{
    "title": "108_hr4512",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medicare Prescription Drug \nImprovement Act''.\n\n      TITLE I--IMPROVEMENT OF MEDICARE PRESCRIPTION DRUG BENEFITS\n\nSEC. 101. PERMITTING THE NEGOTIATION OF FAIR PRICES FOR MEDICARE \n              PRESCRIPTION DRUGS ON BEHALF OF MEDICARE BENEFICIARIES.\n\n     Section 1860D-11 of the Social Security Act, as added by section \n101(a) of the Medicare Prescription Drug, Improvement, and \nModernization Act of 2003 (Public Law 108-173), is amended by striking \nsubsection (i) (relating to noninterference) and by inserting the \nfollowing:\n    ``(i) Authority to Negotiate Prices With Manufacturers.--In order \nto ensure that beneficiaries enrolled under prescription drug plans, \nMA-PD plans, and qualified retiree prescription drug plans pay the \nlowest possible price, the Secretary shall have authority similar to \nthat of the Secretary of Veterans Affairs, Secretary of Defense, and \nthe heads of other Federal agencies and departments that purchase \nprescription drugs in bulk to negotiate contracts with manufacturers of \ncovered part D drugs, consistent with the requirements and in \nfurtherance of the goals of providing quality care and containing costs \nunder this part.''.\n\nSEC. 102. ELIMINATION OF GAP IN COVERAGE OF PRESCRIPTION DRUG BENEFITS.\n\n    (a) In General.--Section 1860D-2(b) of the Social Security Act (42 \nU.S.C. 1395w-102(b)), as added by section 101(a) of the Medicare \nPrescription Drug, Improvement, and Modernization Act of 2003 (Public \nLaw 108-173), is amended by striking paragraph (3) and inserting the \nfollowing:\n            ``(3) Repealed.''.\n    (b) Conforming Amendments.--\n            (1) Section 1860D-2 of the Social Security Act (42 U.S.C. \n        1395w-102) is amended--\n                    (A) in subsection (a)(2)(A)(i)(I), by striking ``, \n                or an increase in the initial coverage limit with \n                respect to covered part D drugs'';\n                    (B) in subsection (b)(2)(A), by striking ``and up \n                to the initial coverage limit under paragraph (3)'';\n                    (C) in subsection (b)(4)(C)(i)--\n                            (i) by striking the comma after ``paragraph \n                        (1)'' and inserting ``and''; and\n                            (ii) by striking ``, and for amounts for \n                        which benefits are not provided because of the \n                        application of the initial coverage limit \n                        described in paragraph (3)'';\n                    (D) in subsection (c)(1), by striking subparagraph \n                (C); and\n                    (E) in subsection (d)(1)(A), by striking ``or an \n                initial coverage limit (described in subsection \n                (b)(3))''.\n            (2) Section 1860D-4(a)(4)(B) of such Act (42 U.S.C. 1395w-\n        104(a)(4)(B)) is amended to read as follows:\n                    ``(B) when prescription drug benefits are provided \n                under this part, a notice of the benefits in relation \n                to the annual out-of-pocket threshold for the current \n                year.''.\n            (3)(A) Section 1860D-14(a) of such Act (42 U.S.C. 1395w-\n        114(a)) is amended--\n                    (i) in paragraph (1), by striking subparagraph (C) \n                and redesignating subparagraphs (D) and (E) as \n                subparagraphs (C) and (D), respectively;\n                    (ii) in paragraph (2), by striking subparagraph (C) \n                and redesignating subparagraphs (D) and (E) as \n                subparagraphs (C) and (D), respectively; and\n                    (iii) in paragraph (4)(A) in the matter preceding \n                clause (i), by striking ``paragraph (1)(D)(ii)'' and \n                inserting ``paragraph (1)(C)(ii)''.\n            (B) Section 1860D-14(c)(1) of such Act (42 U.S.C. 1395w-\n        114(c)(1)) is amended in the second sentence by striking \n        ``subsections (a)(1)(D) and (a)(2)(E)'' and inserting \n        ``subsections (a)(1)(C) and (a)(2)(D)''.\n            (C) Section 1860D-15(e)(1)(B) of such Act (42 U.S.C. 1395w-\n        115(e)(1)(B)) is amended by striking ``paragraphs (1)(D) and \n        (2)(E)'' and inserting ``paragraphs (1)(C) and (2)(D)''.\n            (4)(A) Section 1860D-41(a)(6) of such Act (42 U.S.C. 1395w-\n        151(a)(6)) is amended by striking paragraph (6) and \n        redesignating paragraphs (7) through (18) as paragraphs (6) \n        through (17), respectively.\n            (B) Section 1860D-1(a)(1)(A) of such Act (42 U.S.C. 1395w-\n        101(a)(1)(A)) is amended by striking ``1860D-41(a)(14)'' and \n        inserting ``1860D-41(a)(13)''.\n    (c) Effective Date.--The amendments made by this section shall take \neffect as if included in the enactment of the Medicare Prescription \nDrug, Improvement, and Modernization Act of 2003 (Public law 108-173).\n\n              TITLE II--IMPORTATION OF PRESCRIPTION DRUGS\n\nSEC. 201. SHORT TITLE.\n\n    This title may be cited as the ``Pharmaceutical Market Access Act \nof 2004''.\n\nSEC. 202. IMPORTATION OF PRESCRIPTION DRUGS.\n\n    (a) Nullification of Certain Amendments Made by Public Law 108-\n173.--The Federal Food, Drug, and Cosmetic Act is amended--\n            (1) in section 804 (21 U.S.C. 384), by amending the section \n        to read as if section 1121(a) of Public Law 108-173 had not \n        been enacted;\n            (2) in section 301 (21 U.S.C. 331), by amending the section \n        to read as if section 1121(b)(1) of Public Law 108-173 had not \n        been enacted; and\n            (3) in section 303 (21 U.S.C. 333), by amending the section \n        to read as if section 1121(b)(2) of Public Law 108-173 had not \n        been enacted.\n    (b) Importation of Prescription Drugs.--Section 804 of the Federal \nFood, Drug, and Cosmetic Act (21 U.S.C. 384), as amended by subsection \n(a)(1) of this section, is amended--\n            (1) in subsection (a)--\n                    (A) by striking ``The Secretary'' and inserting \n                ``Not later than 180 days after the date of the \n                enactment of the Pharmaceutical Market Access Act of \n                2003, the Secretary''; and\n                    (B) by striking ``pharmacists and wholesalers'' and \n                inserting ``pharmacists, wholesalers, and qualifying \n                individuals'';\n            (2) in subsection (b)--\n                    (A) by amending paragraph (1) to read as follows:\n            ``(1) require that each covered product imported pursuant \n        to such subsection complies with sections 501, 502, and 505, \n        and other applicable requirements of this Act; and'';\n                    (B) in paragraph (2), by striking ``, including \n                subsection (d); and'' and inserting a period; and\n                    (C) by striking paragraph (3);\n            (3) in subsection (c), by inserting ``by pharmacists and \n        wholesalers (but not qualifying individuals)'' after \n        ``importation of covered products'';\n            (4) in subsection (d)--\n                    (A) by striking paragraphs (3) and (10);\n                    (B) in paragraph (5), by striking ``, including the \n                professional license number of the importer, if any'';\n                    (C) in paragraph (6)--\n                            (i) in subparagraph (C), by inserting ``(if \n                        required under subsection (e))'' before the \n                        period;\n                            (ii) in subparagraph (D), by inserting \n                        ``(if required under subsection (e))'' before \n                        the period; and\n                            (iii) in subparagraph (E), by striking \n                        ``labeling'';\n                    (D) in paragraph (7)--\n                            (i) in subparagraph (A), by inserting ``(if \n                        required under subsection (e))'' before the \n                        period; and\n                            (ii) by amending subparagraph (B) to read \n                        as follows:\n                    ``(B) Certification from the importer or \n                manufacturer of such product that the product meets all \n                requirements of this Act.''; and\n                    (E) by redesignating paragraphs (4) through (9) as \n                paragraphs (3) through (8), respectively;\n            (5) by amending subsection (e) to read as follows:\n    ``(e) Testing.--\n            ``(1) In general.--Subject to paragraph (2), regulations \n        under subsection (a) shall require that testing referred to in \n        paragraphs (5) through (7) of subsection (d) be conducted by \n        the importer of the covered product, unless the covered product \n        is a prescription drug subject to the requirements of section \n        505C for counterfeit-resistant technologies.\n            ``(2) Exception.--The testing requirements of paragraphs \n        (5) through (7) of subsection (d) shall not apply to an \n        importer unless the importer is a wholesaler.'';\n            (6) in subsection (f), by striking ``or designated by the \n        Secretary, subject to such limitations as the Secretary \n        determines to be appropriate to protect the public health'';\n            (7) in subsection (g)--\n                    (A) by striking ``counterfeit or''; and\n                    (B) by striking ``and the Secretary determines that \n                the public is adequately protected from counterfeit and \n                violative covered products being imported pursuant to \n                subsection (a)'';\n            (8) in subsection (i)(1)--\n                    (A) by amending subparagraph (A) to read as \n                follows:\n                    ``(A) In general.--The Secretary shall conduct, or \n                contract with an entity to conduct, a study on the \n                imports permitted pursuant to subsection (a), including \n                consideration of the information received under \n                subsection (d). In conducting such study, the Secretary \n                or entity shall evaluate the compliance of importers \n                with regulations under subsection (a), and the \n                incidence of shipments pursuant to such subsection, if \n                any, that have been determined to be misbranded or \n                adulterated, and determine how such compliance \n                contrasts with the incidence of shipments of \n                prescription drugs transported within the United States \n                that have been determined to be misbranded or \n                adulterated.''; and\n                    (B) in subparagraph (B), by striking ``Not later \n                than 2 years after the effective date of final \n                regulations under subsection (a),'' and inserting ``Not \n                later than 18 months after the date of the enactment of \n                the Pharmaceutical Market Access Act of 2003,'';\n            (9) in subsection (k)(2)--\n                    (A) by redesignating subparagraphs (D) and (E) as \n                subparagraphs (E) and (F), respectively; and\n                    (B) by inserting after subparagraph (C) the \n                following:\n                    ``(D) The term `qualifying individual' means an \n                individual who is not a pharmacist or a wholesaler.''; \n                and\n            (10) by striking subsections (l) and (m).\n\nSEC. 203. USE OF COUNTERFEIT-RESISTANT TECHNOLOGIES TO PREVENT \n              COUNTERFEITING.\n\n    (a) Misbranding.--Section 502 of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 352; deeming drugs and devices to be \nmisbranded) is amended by adding at the end the following:\n    ``(w) If it is a drug subject to section 503(b), unless the \npackaging of such drug complies with the requirements of section 505C \nfor counterfeit-resistant technologies.''.\n    (b) Requirements.--Title V of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 351 et seq.) is amended by inserting after section 505B \nthe following:\n\n``SEC. 505C. COUNTERFEIT-RESISTANT TECHNOLOGIES.\n\n    ``(a) Incorporation of Counterfeit-Resistant Technologies Into \nPrescription Drug Packaging.--The Secretary shall require that the \npackaging of any drug subject to section 503(b) incorporate--\n            ``(1) overt optically variable counterfeit-resistant \n        technologies that are described in subsection (b) and comply \n        with the standards of subsection (c); or\n            ``(2) technologies that have an equivalent function of \n        security, as determined by the Secretary.\n    ``(b) Eligible Technologies.--Technologies described in this \nsubsection--\n            ``(1) shall be visible to the naked eye, providing for \n        visual identification of product authenticity without the need \n        for readers, microscopes, lighting devices, or scanners;\n            ``(2) shall be similar to that used by the Bureau of \n        Engraving and Printing to secure United States currency;\n            ``(3) shall be manufactured and distributed in a highly \n        secure, tightly controlled environment; and\n            ``(4) should incorporate additional layers of non-visible \n        covert security features up to and including forensic \n        capability.\n    ``(c) Standards for Packaging.--\n            ``(1) Multiple elements.--For the purpose of making it more \n        difficult to counterfeit the packaging of drugs subject to \n        section 503(b), manufacturers of the drugs shall incorporate \n        the technologies described in subsection (b) into multiple \n        elements of the physical packaging of the drugs, including \n        blister packs, shrink wrap, package labels, package seals, \n        bottles, and boxes.\n            ``(2) Labeling of shipping container.--Shipments of drugs \n        described in subsection (a) shall include a label on the \n        shipping container that incorporates the technologies described \n        in subsection (b), so that officials inspecting the packages \n        will be able to determine the authenticity of the shipment. \n        Chain of custody procedures shall apply to such labels and \n        shall include procedures applicable to contractual agreements \n        for the use and distribution of the labels, methods to audit \n        the use of the labels, and database access for the relevant \n        governmental agencies for audit or verification of the use and \n        distribution of the labels.''."
}